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Abstract
DOCK8 and MyD88 have been implicated in serologic memory. Here we report antibody
responses were impaired and CD27+ memory B cells were severely reduced in DOCK8-deficient
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tpatients. Toll-like receptor 9 (TLR9)- but not CD40-driven B cell proliferation and
immunoglobulin production were severely reduced in DOCK8-deficient B cells. In contrast,
TLR9-driven expression of AICDA, CD23 and CD86, and activation of NF-κB, p38 and Rac1
were intact. DOCK8 associated constitutively with MyD88 and the tyrosine kinase Pyk2 in normal
B cells. Following TLR9 ligation, DOCK8 became tyrosine phosphorylated by Pyk2, bound the
Src family kinase Lyn and linked TLR9 to a Src-Syk-STAT3 cascade essential for TLR9-driven B
cell proliferation and differentiation. Thus, DOCK8 functions as an adaptor in a TLR9-MyD88
signaling pathway in B cells.
INTRODUCTION
Maintenance of serologic memory requires maturation of naïve B cells into memory B cells
and long-lived plasma cells1. This involves interactions between ligand-receptor pairs that
include CD40 ligand–CD40, BAFF or APRIL with TACI or BCMA, and TLR ligands–
TLRs. TLR9 ligation on naïve B cells promotes proliferation, immunoglobulin secretion and
maturation into memory B cells2–4, and synergizes with CD40 and TACI in causing B cell
activation5, 6. The TLR9 ligand CpG is an adjuvant for antibody responses in mice7, 8.
Defective B cell responses to TLR9 ligation has been observed in patients with common
variable immune deficiency characterized by poor antibody production and decreased
generation of memory B cells and plasma cells9.
Following ligand binding, TLR9 associates with and signals via the adaptor protein MyD88
(ref. 10). Resting B cells express several TLRs including TLR4 in mice and TLR6, 7, 9 and
10 in mice and humans. MyD88 is important for antibody responses to T dependent (TD)
antigens administered with lipopolysaccharide (LPS) or CpG as adjuvants11–13, although
exceptions have been noted14. MyD88 does not appear to play a role in the antibody
response to TD antigens administered with alum as adjuvant, or certain bacterial
antigens15–17, but is important for the antibody response to viruses12, 18, 19.
The dedicator of cytokinesis-8 (DOCK8) is one of eleven members of the DOCK180
superfamily20. DOCK proteins have characteristic DOCK homology region-1 (DHR-1) and
DHR-2 domains. The DHR-1 domain is important for DOCK protein targeting to
membranes, through its binding of phosphatidylinositol (3,4,5)-triphosphate
(PtdIns(3,4,5)P3)21. The DHR2 domain binds to Rac-Rho family GTPases, and can function
as an exchange factor for these GTPases21. The biological functions of DOCK8 include
regulation of cell migration, morphology, adhesion and growth20. A mouse genetic screen
for mutations that disrupt the persistence of the antibody response identified loss-of-function
mutations in Dock8 (ref. 23). DOCK8 mutant mice exhibit T cell lymphopenia, and their B
cells fail to develop into marginal zone (MZ) B cells and to persist in germinal centers
(GCs) and undergo affinity maturation. Reconstitution experiments indicate that DOCK8
expression in B cells is important for the normal persistence of GCs22, suggesting that
DOCK8 expression in B cells plays a key role in serologic memory.
Recently, mutations of DOCK8 have been shown to account for a combined
immunodeficiency in humans characterized by increased susceptibility to viral skin
infections, severe allergy, elevated serum IgE, eosinophilia, T cell lymphopenia and
impaired antibody responses23, 24. We analyzed the response of B cells from DOCK8-
deficient patients to the TLR9 ligand CpG. DOCK8 was found to mediate a novel MyD88
signaling pathway, which is essential for TLR9-driven B cell proliferation and
immunoglobulin production.
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Antibody response and memory B cells in DOCK8 deficiency
Ten patients aged 3.5–15 years with homozygous mutations in DOCK8 were studied
(Supplementary Table 1). None had detectable DOCK8 protein in lysates of peripheral
blood mononuclear cells (PBMCs) or Epstein-Barr virus (EBV) transformed B cells (data
not shown). All had typical clinical characteristics of DOCK8 deficiency (Supplementary
Table 2). Five patients, from whom serum was available prior to initiation of
immunoglobulin replacement therapy, showed defective IgG antibody response to tetanus
toxoid (TT), hepatitis B vaccine (Hep. B), TT-conjugated Haemophilus influenzae type B
vaccine (HiB) and conjugated pneumococcal polyvalent vaccine (PV) (Table 1). The IgM
TT antibody response was significantly decreased in these patients (Supplementary Fig. 1).
Two of these patients, aged 8 and 15 years mounted a brisk early antibody response 8 weeks
after a booster dose of TT, which fell below the protective level twelve and fifteen months
later (Fig. 1a). This response is in contrast to >99% of normal children, in whom protective
antibody titers persist five years after TT booster vaccination 25, 26.
Flow cytometry analysis of PBMCs revealed that the percentage of CD3+ T cells was
significantly decreased in the patients compared to age-matched healthy controls, as
previously reported23, 24, while the percentage of CD19+ B cells was normal or increased
(Fig. 1b). There was a severe deficiency in the percentage of circulating CD19+CD27+
memory B cells in all patients examined, with CD19+CD27− naïve B cells accounting for
virtually all (>95%) their B cells (Fig. 1c,d). The percentage of circulating IgD+CD27+ MZ-
like B cells was decreased in the patients compared to controls (Supplementary Fig. 2),
consistent with the findings in DOCK8 mutant mice22. These results indicate that DOCK8 is
important for the generation of memory B cells and serologic memory in humans.
Impaired B cell activation by CpG in DOCK8 deficiency
The TLR9 ligand CpG ODN 2006 (thereafter referred to as CpG) acts selectively on human
B cells27, and has no detectable effects on non-B cells28. PBMCs from DOCK8-deficient
patients were severely deficient in their capacity to proliferate and to secrete IgM and IgG in
response to CpG stimulation, compared to PBMCs from age-matched normal subjects,
which included shipping controls (Fig. 2a). In contrast, DOCK8-deficient PBMCs
proliferated and secreted IgM normally following stimulation with anti-CD40 plus
interleukin 21 (IL-21), and secreted about half the amount of IgG as normal PBMCs (Fig.
2b). PBMCs from the patients proliferated and secreted IgE in response to anti-CD40 plus
IL-4 to an extent comparable to normal PBMCs (Fig. 2c).
The severely impaired response of DOCK8-deficient PBMCs to CpG could not be simply
explained by the lack of memory B cells. Highly purified naïve B cells from normal subjects
(>95% CD27−, Supplementary Fig. 3a), proliferated to CpG to an extent comparable to total
B cells isolated from the same subjects (Fig. 2d). Consistent with previous reports2–4, the
amounts of IgM and IgG secreted by CpG-stimulated naïve B cells were reduced to
respectively ~one-half and ~one-third of those secreted by CpG-stimulated total B cells (Fig.
2d). In contrast, purified B cells from DOCK8-deficient patients, which were virtually all
naive, completely failed to proliferate and to secrete IgM and IgG in response to CpG (Fig.
2d). Proliferation and secretion of IgM and IgG in response to anti-CD40 plus IL-21 was
comparable in normal naïve B cells and DOCK8-deficient purified B cells (Supplementary
Fig. 3b). The decreased IgG secretion of DOCK8-deficient PBMCs to anti-CD40 plus IL-21
was most likely secondary to lack of memory B cells, because purified normal naïve B cells
exhibited a comparable decrease in IgG secretion in response to anti-CD40 plus IL-21
relative to total B cells (Supplementary Fig. 3b). The failure of B cells from DOCK8-
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tdeficient patients to respond to CpG was not due to increased apoptosis and cell death, as
determined by staining with Annexin V and propidium iodide (Supplementary Fig. 4). These
results indicate that B cells from DOCK8-deficient patients have an intrinsic and selective
defect in their ability to respond to CpG.
CpG activates known pathways in DOCK8 deficient B cells
CpG stimulation of B cells induces the expression of AICDA, which encodes activation-
induced cytosine deaminase (AID) that is critical for isotype switching, and upregulates the
expression of the low affinity IgE receptor CD23 and the co-stimulatory molecule CD86
(refs. 4,29). CpG stimulation induced comparable AICDA mRNA expression in PBMCs and
B cells from DOCK8-deficient patients and controls (Fig. 3a), and comparable increases in
the percentage of CD19+ B cells that express CD23 and CD86 (Fig. 3b,c). The mean
fluorescence intensity (MFI) of these antigens on B cells was comparable between DOCK8-
deficient patients and controls (Fig. 3b,c). NF-κB and the MAP kinase p38 are activated by
CpG stimulation and play an important role in the induction of AICDA, CD23 and CD86
expression30–32. CpG stimulation caused comparable IκBα and p38 phosphorylation in
EBV-B cells and PBMCs from DOCK8-deficient patients and controls (Fig. 3d and data not
shown). CpG-driven IL-6 secretion by EBV-B cells was not significantly different between
patients and controls (Fig. 3e). CpG stimulation causes plasmacytoid dendritic cells (pDCs)
to secrete interferon-α (IFN-α). This induction requires MyD88-dependent activation of
IRF7 (ref. 33). Stimulation of PBMCs with the CpG type A ODN 2216, which activates
TLR9 in human pDCs, resulted in comparable secretion of IFN-α in patients and controls
(Fig. 3f)
The DHR2 domain of DOCK proteins can activate Rac and/or Cdc42 (ref. 21) and CpG
activates Rac1 in DCs34. To examine Rac1 activation, a fusion protein of glutathione-S-
transferase (GST) and the GTPase binding domain of p21-activated kinase (GST-PAK) was
used to precipitate GTP-bound Rac1 and Cdc42 from cell lysates, followed by
immunoblotting with antibodies to Rac1 and Cdc42. Stimulation with CpG resulted in
comparable Rac1 activation in EBV-B cells from normal and DOCK8-deficient subjects
(Fig. 3g), but caused no detectable Cdc42 activation (data not shown). Thus, CpG activates
Rac1 in B cells, but DOCK8 is not essential for this activation.
DOCK8 dependent activation of STAT3 by CpG in B cells
STAT3 is important for B cell proliferation and differentiation in response to anti-CD40 plus
IL-21 (ref. 35,36). Stimulation of normal PBMCs with CpG induced STAT3
phosphorylation on residue Y705 (Fig. 4a). In contrast, CpG-driven, but not IL-21-driven,
STAT3 phosphorylation was defective in DOCK8-deficient PBMCs (Fig. 4a). CpG-driven,
but not IFN-α induced, STAT3 phosphorylation was defective in purified DOCK8-deficient
B cells (Fig. 4b), indicating that the defect is B cell autonomous. IL-6 and IL-21 caused
comparable STAT3 phosphorylation in purified B cells from patients and controls (Fig. 4c).
Densitometry scanning analysis demonstrated that CpG-driven STAT3 phosphorylation in B
cells from DOCK8-deficient patients was 18±7% of control (n = 3 each, P < 0.01), whereas
IL-21-driven STAT3 phosphorylation was comparable (Fig. 4d). The defect in CpG-driven
STAT3 phosphorylation in DOCK8-deficient B cells was not secondary to lack of memory
B cells, because CpG caused comparable STAT3 phosphorylation in purified naïve B cells
and unfractionated B cells from normal controls (Fig. 4e). These results demonstrate that
DOCK8 deficiency selectively impairs CpG-driven STAT3 phosphorylation in B cells.
The role of STAT3 in CpG-driven B cell proliferation and differentiation was investigated
by examining PBMCs from six patients with autosomal dominant hyper-IgE syndrome (AD-
HIES), resulting from different dominant-negative mutations in STAT3 (Supplementary
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tTable 3). PBMCs from these patients had significantly impaired proliferation and IgG
secretion following stimulation with CpG (Fig. 4f). There was no significant difference
between PBMCs from AD-HIES patients and controls in their ability to proliferate and
secrete IgE in response to anti-CD40 plus IL-4 (Fig. 4g). As previously reported35, PBMCs
from AD-HIES patients failed to proliferate and secrete IgG in response to anti-CD40 plus
IL-21 (Supplementary Fig. 5).
Because IL-6 caused STAT3 phosphorylation in DOCK8-deficient B cells, we examined
whether exogenous IL-6 corrects their defective response to CpG. Addition of rIL-6 to
DOCK8-deficient PBMCs failed to correct their defective proliferation and IgG secretion in
response to CpG (Fig. 4h, and data not shown). These results indicate that in addition to
STAT3 phosphorylation, other signals that are important for CpG-driven B cell proliferation
and differentiation are impaired in DOCK8-deficient B cells.
TLR9 protein expression was comparable in B cells from patients and controls
(Supplementary Fig. 6a). Correct subcellular localization of TLR9 is essential for its
function37. Lack of DOCK8 might result in TLR9 mislocalization, which could interfere
with the ability of TLR9 to activate STAT3. EBV-B cells from normal subjects and
DOCK8-deficient patients were stimulated for 90 min with CpG, permeabilized and
simultaneously stained for TLR9 and either endoplasmic reticulum (ER Tracker®), the early
endosomal marker EEA-1 or the late endosomal-lysosomal markers LAMP-1 (also known
as CD107a). Fluorescent microscopy revealed that the subcellular localization of TLR9 was
comparable in normal and DOCK8-deficient EBV-B cells (Supplementary Fig. 6b). Thus
DOCK8 has no detectable role in TLR9 trafficking in B cells.
Syk is downstream of DOCK8 in CpG activated B cells
The tyrosine kinase Syk activates STAT3 in B lymphoma cells38, 39. Stimulation of normal
PBMCs with CpG caused Syk phosphorylation on residue Y352, the target of Src kinases
(Fig. 5a). In contrast, it caused negligible Syk phosphorylation in DOCK8-deficient PBMCs
(Fig. 5a). The defect in Syk phosphorylation was specific to CpG because B cell receptor
(BCR) crosslinking with anti-IgM caused comparable Syk phosphorylation in patients and
controls (Fig. 5b). Densitometry scanning analysis demonstrated that CpG-driven Syk
phosphorylation in PBMCs from DOCK8-deficient patients was 16±8% of controls, (n = 3
each, P < 0.001), while BCR-driven Syk phosphorylation was not significantly different
(Fig. 5c).
The pentapeptide Syk inhibitior SYKINH-61 was used to examine whether Syk activation is
important for CpG-driven STAT3 phosphorylation. SYKINH-61 inhibited CpG-driven
STAT3 phosphorylation in normal PBMCs (85±5% inhibition, n = 3), but had no effect on
IL-21-driven STAT3 phosphorylation (Fig. 5d), or CpG-driven phosphorylation of p38 (data
not shown). Moreover, SYKINH-61 inhibited CpG-driven proliferation and IgG production
in normal PBMCs in a dose-dependent manner, but had no effect on CD40–IL-21-driven
proliferation and IgG production (Fig. 5e,f).
The role of Syk in CpG-driven STAT3 phosphorylation was verified using RNA silencing.
The mouse B cell line CH12 faithfully reproduced the response of primary human B cells to
CpG stimulation by exhibiting Pyk2, Syk and STAT3 phosphorylation (Supplementary Fig.
7a). shRNA knockdown (KD) of Syk, but not introduction of non-silencing (NS) shRNA,
strongly reduced Syk protein expression and strongly inhibited CpG-driven STAT3
phosphorylation in CH12 cells (Supplementary Fig. 7b–d). These results place Syk upstream
of STAT3 activation by CpG in B cells.
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tCpG may bind to sensors other than TLR9 (ref. 34). To determine if DOCK8 dependent
CpG-driven phosphorylation of Syk and STAT3 proceeds through the engagement of TLR9
and its adaptor protein MyD88, we compared the response of purified splenic B cells (>95%
B220+ cells) from Tlr9−/− and Myd88−/− mice and their genetically matched wild-type
controls. CpG stimulation resulted in the phosphorylation of Syk and STAT3 in B cells from
wild-type mice (Fig. 5g,h), as in normal human B cells. In contrast, CpG stimulation caused
minimal Syk and STAT3 phosphorylation in B cells from Tlr9−/− and Myd88−/− mice.
Furthermore, CpG failed to cause proliferation and IgG secretion by B cells from Tlr9−/−
and Myd88−/− mice (Supplementary Fig. 8). Together, these results indicate that CpG
engages TLR9–MyD88 to cause DOCK8-dependent phosphorylation of Syk and STAT3,
which is essential for B cell proliferation and differentiation.
CpG activates a Pyk2-Src-Syk-STAT3 cascade in B cells
Stimulation of normal PBMCs with CpG resulted in tyrosine phosphorylation of proteins
with molecular weights that correspond to those of Src family kinases (54–56 kDa), their
target Syk (72 kDa), and Pyk2 (110 kDa), a tyrosine kinase that functionally interacts with
Src kinases (Fig. 6a). In contrast, it caused minimal protein tyrosine phosphorylation in
PBMCs from DOCK8-deficient patients. This defect was selective to CpG stimulation,
because BCR crosslinking caused comparable protein tyrosine phosphorylation in PBMCs
from DOCK8-deficient patients and controls (data not shown), consistent with the normal
activation of B cells from DOCK8 mutant mice following BCR crosslinking22.
Pyk2 is auto-phosphorylated on tyrosine residue Y402 (ref. 40). Activated Src family
kinases (thereafter referred to as Src) are autophosphorylated on Y residues that correspond
to Y416 in Src40, and are recognized by anti-pY416Src. Immunoblotting lysates of PBMCs
with phosphospecific mAbs to pY402Pyk2 and pY416Src demonstrated that stimulation
with CpG caused Pyk2 and Src phophorylation in normal PBMCs (Fig. 6b). In contrast,
CpG stimulation caused minimal phosphorylation of Pyk2 and Src in DOCK8-deficient
PBMCs (Fig. 6b), demonstrating that CpG-driven tyrosine phosphorylation of Pyk2 and Src
is DOCK8 dependent. Pyk2 and Src were phosphorylated after CpG stimulation of B cells
from wild-type, but not Myd88−/− mice (Fig. 6c), indicating that TLR9-driven
phosphorylation of Pyk2 and Src, like that of Syk and STAT3, is dependent on MyD88.
We used selective inhibitors of Pyk2 and Src to examine the roles of these kinases in CpG-
driven activation of B cells. The Pyk2 inhibitor Tyrphostin A9 strongly inhibited CpG-
driven tyrosine phosphorylation of Pyk2, Src, Syk and STAT3 (Fig. 6d-g). In three
experiments the inhibition was 84±3% for Pyk2, 81±6% for Src, 95±4% for Syk and 97±2%
for STAT3. Tyrphostin A9 had no detectable effect on IL-6 driven STAT3 phosphorylation,
or CpG-driven p38 phosphorylation (data not shown). Tyrphostin A9 strongly inhibited
CpG-driven IgG secretion by 90±2% (n = 3, P < 0.01), but not CD40–IL-21 driven IgG
secretion (Fig. 6h). Similar results were obtained with the structurally different Pyk2
inhibitor PF562271 (data not shown). The role of Pyk2 in CpG-driven STAT3
phosphorylation was verified using shRNA knockdown in CH12 B cells (Supplementary
Fig. 7b–d).
The Src inhibitor PP2 had a modest effect on CpG-driven Pyk2 phosphorylation (Fig. 6d),
but more strongly inhibited CpG-driven phosphorylation of Src, Syk and STAT3 (Fig. 6e–
g). In three experiments, inhibition by PP2 was 28±13% for Pyk2, 80±8% for Src, 71±9%,
for Syk and 63±11% for STAT3. The modest inhibition of Pyk2 phosphorylation is
consistent with the ability of Src to activate Pyk2 (ref. 40), and suggests feedback
amplification of Pyk2 activation by Src. The less than complete inhibition of Syk and
STAT3 phosphorylation could be due to the ~20% residual Src activity. Alternatively, a Src-
independent link between Pyk2 and Syk–STAT3 might exist. PP2 inhibited CpG-driven IgG
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tsecretion by 70±12% (n = 3, P < 0.05), but had no effect on CD40–IL-21 driven IgG
secretion (Fig. 6h). Similar results were obtained with the structurally different Src kinase
inhibitor SU6656 (data not shown). Taken together the above results suggest that TLR9
ligation activates a Pyk2-Src-Syk cascade that results in STAT3 phosphorylation.
A DOCK8-MyD88-Pyk2 complex links to Lyn
Our results place DOCK8 and Pyk2 downstream of MyD88. To examine whether DOCK8
associates with MyD88, 293T cells were co-transfected with vectors encoding Myc-tagged
DOCK8 and HA-tagged MyD88, or HA-tagged myocardin-related transcription factor-A
(MRTF-A) as a control. DOCK8 was found to co-precipitate with MyD88, but not with
MRTF-A (Fig. 7a). To examine whether DOCK8 associates with MyD88 in B cells,
DOCK8 immunoprecipitates from normal EBV-B cells were probed for MyD88. DOCK8
associated weakly with MyD88 in unstimulated cells, but this association increased
following CpG stimulation (Fig. 7b).
Pyk2 was reported to interact with MyD88 in macrophages41. This interaction was mapped
to the proline-rich C-terminal region of Pyk2 and the death domain of MyD88. Probing of
MyD88 immunoprecipitates from normal EBV-B cells with mAb to Pyk2 revealed that
Pyk2 associates with MyD88 (Fig. 7c). This association was not altered detectably by CpG
stimulation and was independent of DOCK8, as Pyk2 co-precipitated with MyD88 from
lysates of EBV-B cells from DOCK8-deficient patients (Fig. 7c). Pyk2 was readily detected
in DOCK8 immunoprecipitates from normal EBV-B cells (Fig. 7d). This association
increased following CpG stimulation. The constitutive association of DOCK8 and Pyk2 was
independent of MyD88 and was observed in EBV-B cells from a MyD88-deficient patient
that express no detectable MyD88 protein (Fig. 7d). However, CpG stimulation did not
increase the association of DOCK8 and Pyk2 in the absence of MyD88. These results
suggest that DOCK8 forms a complex with MyD88 and Pyk2.
The YEEVK motif (amino acids 628–632)in the DHR1 domain of DOCK8 also exists in
cofilin-1 where it is a target of Pyk2 phosphorylation42. This motif is located within a
sequence in DOCK8 (HNKSPDFYEEVKIKL, amino acids 621–635), which is a potential
binding site for the SH2 domain of Src. Probing DOCK8 immunoprecipitates from EBV-B
cells with mAbs to phosphotyrosine and Src revealed that CpG stimulation caused tyrosine
phosphorylation of DOCK8 and its association with Src (Fig. 7e). Both events were
abrogated by the Pyk2 inhibitor Tyrphostin A9. The Src family member Lyn is expressed
preferentially in B cells43. Probing Lyn immunoprecipitates with a pY416Src mAb
demonstrated that CpG stimulation causes tyrosine phosphorylation of Lyn in normal B cells
(Fig. 7f). Furthermore, CpG stimulation caused robust association of Lyn with DOCK8,
which was abrogated by addition of the Pyk2 inhibitor Tyrphostin A9 (Fig. 7g). These
results indicate that TLR9 ligation in B cells causes Pyk2-dependent DOCK8
phosphorylation and recruitment of Src and/or Lyn.
DISCUSSION
We present evidence that DOCK8 functions as an adaptor that links TLR9 via MyD88 to a
Pyk2-Src-Syk-STAT3 signaling cascade, and we demonstrate that this pathway is essential
for TLR9-driven B cell proliferation and immunoglobulin production.
DOCK8-deficient patients had impaired ability to sustain a protective antibody response,
similar to DOCK8 mutant mice, and lacked circulating CD27+ memory B cells. DOCK8-
deficient B cells failed to proliferate and secrete IgM and IgG in response to CpG. This
defect is cell-autonomous, specific to CpG and not accounted for by the lack of memory B
cells. Because of constraints in obtaining sufficient amounts of blood from children for B
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tcell purification, our experiments used PBMCs, which were stimulated with the B cell
selective TLR9 ligand CpG ODN2006, and/or EBV-B cells. Whenever possible, purified B
cells from at least two patients were also used.
CpG stimulation normally upregulated the expression of AICDA, CD23 and CD86 in
DOCK8-deficient B cells and resulted in normal activation of NF-κB and p38, and normal
IRF7-dependent secretion of IFN-α in DOCK8-deficient PBMCs, indicating that these
events occur independently of DOCK8. Unexpectedly, given the reported GEF activity of
DOCK proteins for small GTPases21, CpG activated Rac1 independently of DOCK8. CpG
activation of Rac1 in pDCs uses a non-TLR9 sensor and DOCK2 (ref. 34). A similar
pathway could be operative in B cells.
A central finding in this study is that CpG causes STAT3 phosphorylation in B cells in a
DOCK8-dependent manner. Impaired STAT3 phosphorylation in DOCK8-deficient B cells
was specific for CpG stimulation, and was not secondary to the lack of memory B cells. The
critical role of STAT3 in CpG-driven B cell proliferation and differentiation was
demonstrated by the observation that these responses were impaired in patients with
dominant-negative mutations in STAT3. The failure of IL-6, which caused STAT3
phosphorylation in DOCK8-deficient B cells, to correct their defective response to CpG
indicates that other DOCK8-dependent signals are also required for CpG-driven B cell
proliferation and IgG secretion. These may include signals delivered by Pyk2, Src and Syk
which trigger the activation of phospholipase C-γ, phosphatidylinositol-3-OH kinase and B
cell linker protein (BLNK)44–46.
Syk was shown to play a critical role in CpG-driven STAT3-dependent B cell proliferation
and differentiation. CpG stimulation of B cells caused Syk phosphorylation, which was
severely impaired in DOCK8-deficient B cells, placing Syk downstream of DOCK8. The
Syk selective inhibitor SYKINH-61 blocked CpG-driven STAT3 phosphorylation, placing
Syk upstream of STAT3, and inhibited CpG-driven B cell proliferation and IgG secretion.
CpG stimulation of B cells caused DOCK8-dependent phosphorylation of Pyk2 and Src.
DOCK8 was demonstrated to link TLR9-MyD88 to a Pyk2-Src-Syk-STAT3 cascade in B
cells, which was shown to be essential for TLR9-driven B cell activation. The observation
that CpG-driven phosphorylation of Pyk2, Src, Syk and STAT3, and B cell proliferation and
differentiation were dependent on TLR9 and MyD88, indicate that CpG engagement of
TLR9-MyD88 results in DOCK8-dependent B cell activation. CpG-A DNA has been
reported to induce tyrosine phosphorylation of proteins, including Syk, in monocytes and
macrophages independently of TLR9 and MyD88 (ref. 47). Differences in the ODNs and
target cells used may account for the difference in the requirement for TLR9 and MyD88.
DOCK8 was found to exist in a complex with MyD88 and Pyk2. MyD88 was not essential
for DOCK8-Pyk2 association, and DOCK8 was not essential for MyD88-Pyk2 association,
although it was essential for Pyk2 phosphorylation following TLR9 ligation. Following CpG
stimulation, DOCK8 became more strongly associated with MyD88 and Pyk2, underwent
tyrosine phosphorylation and associated with Src and/or Lyn. We propose the following
model of DOCK8 dependent TLR9 signaling. Ligation of TLR9 by CpG causes recruitment
and stabilization of a preexisting MyD88-Pyk2-DOCK8 complex, which results in
autophosphorylation and activation of Pyk2. Pyk2 then phosphorylates DOCK8 causing it to
recruit Src kinases, including Lyn, via their SH2 domain, releasing them from auto-
inhibition. Src then activates Syk, which drives STAT3 activation. The proposed pathway is
likely a simplification. Src and Syk can phosphorylate Pyk2 (ref. 40), and Src and Pyk2 can
synergize to cause STAT3 phosphorylation48, 49. Future experiments will determine whether
the DOCK8-dependent TLR9-MyD88 signaling pathway we have identified is used by other
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treceptors that signal via MyD88 in B cells and other cells. Preliminary data indicates that
this pathway is activated by TLR4 ligation in PBMCs (data not shown).
DOCK8 deficiency results in impaired immunological synapse in B cells22 and may impair
the ability of T cells and DCs to drive antibody production by B cells. Mice with selective
DOCK8 deficiency in B cells, and mice in which the interaction between MyD88 and
DOCK8 is disrupted will help define the contribution of DOCK8-dependent MyD88
signaling in B cells to the impaired serologic memory in DOCK8 deficiency. Given that
TLR9 ligands are vaccine adjuvants and the role of TLR9 in autoantibody responses to self
DNA50, the TLR9 signaling pathway we have described may be important for developing
better vaccines and understanding and treating autoantibody-mediated diseases.
Methods
Patients
Ten patients with established DOCK8 mutations and six with STAT3 mutations were
studied. Informed consent was provided by adult donors or by the children’s parents or
guardian. Protocols used in the human studies have been approved by the Committee on
Clinical Investigations at Children’s Hospital, Boston, MA, USA.
Cell preparation
Human PBMCs were isolated from heparinized blood obtained from patients and normal
donors using Ficoll-Hypaque (GE Healthcare). Naïve and total B cells were purified from
PBMCs by negative selection using the B cell isolation Kits II (Miltenyi Biotec) according
to the manufacturer’s recommendation and contained >96% CD19+ cells. Cells were
suspended in RPMI-1640 containing 10% heat-inactivated FCS (Hyclone), 2 mM L-
glutamine, 50 μg/ml streptomycin and 100 U/ml penicillin (medium). Epstein-Barr virus
(EBV) transformed cell lines on patients and controls were established as described51.
Cell cultures
PBMCs (1 × 106 and 1.5 × 106 cells/ml for proliferation and immunoglobulin production
respectively) or B cells (1.5 × 106 cells/ml) were cultured with medium, CpG ODN 2006 or
2216 (0.1 μM, Invivogen), or anti-CD40 (5 μg/ml, clone 626.1) in the presence of either
recombinant (r) human interleukin 21 (IL-21, (50 ng/ml, Miltenyi Biotech), or rIL-4 (5 ng/
ml, R&D Systems). The following kinase inhibitors were used: Syk inhibitor (SYKINH-61,
a kind gift of F. Uckun, University of Southern California, Los Angeles); Pyk2 inhibitor
(Tyrphostin A9, AG 17), and Src inhibitor (PP2) from EMD biosciences. Proliferation was
assayed 4 days later by assaying for 3H-thymidine incorporation. IgM, IgG and IgE
production was measured in 14-day culture supernatants by ELISA as previously
described52. CpG-mediated upregulation of CD23 and CD86 expression was analyzed by
flow cytometry after 48 h. IL-6 and IFN-α in culture supernatants were measured after 24 h
using ELISA kits from Invitrogen. Apoptosis was evaluated on day 3 after stimulation. IgM
specific tetanus toxoid (TT) antibody in sera was assayed using ELISA kit from IBL
International.
Flow cytometry
Anti-human monoclonal antibodies to the following were used for staining: CD3 (HIT3a),
CD19 (HIB19), CD27 (M-T271), CD23 (M-L233), CD86 (2331(FUN-1)) and IgD (IA6-2)
(BD Biosciences); CD123 (AC145) and BDCA-4 (AD5-17F6) (Miltenyi) with the
appropriate isotype controls. Annexin V–FITC was purchased from Biovision Inc. Data
collected with a FACSCalibur cytometer (BD Biosciences) were analyzed with CellQuest
software (BD Biosciences) or FlowJo software (TreeStar).
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RNA was extracted from cultured B cells on day 5 using TRIzol (Invitrogen) and was
reverse transcribed by Supercript II RT (Invitrogen) according to manufacturer’s
instructions. Q-PCR for AICDA was performed using primers and an ABI Prism 7300
sequence detector from Applied Biosystems. Relative RNA expression normalized to
GAPDH RNA abundance was calculated by the relative standard curve method as outlined
in the manufacturer’s technical bulletin (Applied Biosystems).
Immunoblot analysis
PBMCs, B cells or EBV-transformed B cell lines (1 × 106 cells/condition) were
unstimulated or stimulated with either CpG (2.5 μM), IL-21 (10 ng/ml), IFN-α (1000 U/ml),
Biosource), rIL-6 (2 ng/ml, R&D systems) or anti-human IgM (10 μg/ml, Jackson Immuno
Research Labs). Total cell lysates were then separated by SDS-PAGE gel electrophoresis
and transferred to nitrocellulose membranes. The following antibodies were used for
immunoblot analysis: anti-DOCK8 (#HPA003218, Sigma-Aldrich); anti-STAT3 (79D7),
anti-BLNK (#3587), anti-Pyk2 (5E2), anti-Lyn (C13F9) and antibodies to phosphorylated
p38 (D3F9), IκBα (ser32/36, 5A5), STAT3 (Tyr705, D3A7), Syk (Tyr352, #2701), Pyk2
(Tyr402, #3291), and Src family (Tyr416, #2101) (Cell Signaling); anti-IκBα (sc-847), anti-
IKKγ (Fl-419), and anti-HA (Santa Cruz Biotechnology); anti-Syk (4D10.1), anti-Src (CT,
NL19), anti-Myc (9E10), and anti-phosphotyrosine (4G10) (Millipore). The densitometric
analysis of the scanned bands was evaluated using the NIH Image program J 1.440 software.
Transient Transfections and Co-Immunoprecipitation
A wild-type human DOCK8 construct was generated with a Myc tag by PCR amplification
of pCR4-TOPO human DOCK8 cDNA (Open Biosystems) using standard cloning
techniques. 293T cells were transfected with plasmids encoding Myc-tagged DOCK8, HA-
tagged MyD88, and HA-tagged MRTF-A (R. Treisman, Cancer Research, UK), using
Lipofectamine LTX (Invitrogen). After 16 h, cells were lysed with buffer containing 0.75%
NP-40. Immunoprecipitation was performed using a monoclonal anti-HA (HA-7) agarose
conjugate (Sigma-Aldrich), were separated by SDS-PAGE, transferred to nitrocellulose
membranes, and immunoblotted with antibodies against Myc, MyD88 and HA. For
immunoprecipitation (IP) experiments in EBVs, IP and MyD88 blotting was done with anti-
MyD88 (H00004615-PW2 pair, Novus).
Rac1 precipitation assay
RAC1 activation was assessed by pull-down from lysates with a fusion protein of
gluthatione-S-transferase and the PBD domain of PAK1 (Pierce Laboratories) as previously
described53. Immunoblot of precipitated samples and aliquots of the cell extracts for loading
controls was then performed with RAC1 antibody (Pierce Laboratories).
Subcellular localization of TLR9 in CpG stimulated B cells
EBV transformed B cells stimulated with CpG for 90 min, were spun onto poly-D-lysine-
coated coverslips (50 μg/ml, Sigma). Localization of TLR9 to endoplasmic reticulum was
confirmed using ER Tracker® Red marker and Alexa 488-conjugated (green) anti-TLR9
(26C593.2, Imgenex Corp). Cells were loaded with ER Tracker® Red (Invitrogen) per
vendor’s protocol, fixed in 4% paraformaldehyde, permeabilized with 0.04% saponin in 1%
BSA54 and incubated with anti-TLR9. Coverslips were mounted on slides using Prolong
Gold with DAPI antifade mounting medium (Invitrogen). Cells on coverslips were fixed in
4% paraformaldehyde, permeabilized with 0.25% Triton X-100, blocked with 10% FCS in
PBS, incubated with Early endosome (EEA1, 1G11) and late endosomes/lysosomes
(LAMP1, H4A3) monoclonal antibodies (Abcam) for 1 h at 25°C, washed and stained with
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tAlexa 555-conjugated (red) anti-mouse IgG (Invitrogen). Counterstaining with TLR9
antibody and slide mounting was performed as described above. All images were acquired
using a Nikon Eclipse Ti inverted microscope, and were processed using NIS elements
AR3.0 software and/or Adobe Photoshop.
Short hairpin RNA (shRNA)- mediated Knockdown (KD) of Pyk2 and Syk expression in
CH12 cells
pGIPZ lentiviral vectors encoding green fluorescent protein (GFP) as well as shRNAs
specific for murine Pyk2, Syk and a non-silencing (NS, scrambled) plasmid were purchased
from Open Biosystems. CH12 cells were transfected by electroporation with 0.5 μg/ml of
each plasmid and transduced cells were selected using puromycin. GFP-positive cells were
subcloned and tested for Pyk2 and Syk protein expression by immunoblotting.
Mice
TLR9- and Myd88-deficient and the corresponding C57BL/6 and BALB/c wild-type control
mice were used at 8–12 weeks of age according to the guidelines of the Animal Care
Committee of Children’s Hospital, Harvard Medical School, Boston, MA, USA.
Mouse Cell cultures
B cells were purified from splenic cell suspensions by negative selection using CD43-
conjugated magnetic beads from Miltenyi. Purified B cells (>95% B220+) were suspended
in complete medium containing 50 μM β-mercaptoethanol and were cultured (106 cells/ml)
with medium or CpG ODN 1826 (3 μg/ml, Invivogen). Proliferation was assayed day 4 by
measuring 3H-thymidine incorporation. Day 6 IgG was measured in culture supernatants by
ELISA. For immunoblot studies CpG ODN 1826 (2.5 μM) and mouse rIL-21 (10 ng/ml,
R&D Systems) were used.
Statistical analysis
Student t-test was used for statistical analysis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Impaired antibody responses, failure to maintain serologic memory and decreased
memory B cells in DOCK8 deficient patients
(a) Serial antibody titers after re-immunization with TT in two DOCK8 deficient patients
aged 8 (Pt. 4) and 15 years (Pt. 7). The dotted line represents the lower limit of the
protective antibody titer. (b) Percentage of CD3+ (T) cells and CD19+ (B) cells in PBMCs
from DOCK8 deficient patients (Pt) and controls (C (c) Representative flow cytometry
analysis of CD19 and CD27 expression by PBMCs from DOCK8 deficient patients and
controls. (d) Percentage of CD27+ memory B cells and CD27− naïve B cells in the CD19+ B
cell population of DOCK8 deficient patients and controls. Each symbol (b,d) represents an
individual subject; small horizontal lines indicate the mean. *P<0.05 and **P<0.001
(Student’s t-test).
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tFigure 2. Impaired CpG driven B cell proliferation and immunoglobulin (Ig) production to CpG
in DOCK8 deficient patients
(a–c) Proliferation and Ig secretion by PBMCs from DOCK8 deficient patients (Pt) and
controls (C) in response to stimulation with CpG (a), anti-CD40 + IL-21 (b) and anti-CD40
+ IL-4 (c). Not all 10 patients could be studied in each assay. (d) Proliferation, and secretion
of IgM and IgG by highly purified total and naïve B cells from controls (n=3 each) and
purified total B cells from DOCK8 deficient patients (n=2 each) in response to stimulation
with CpG (mean and s.e.). Each symbol (a,b,c) represents an individual subject; small
horizontal lines indicate the mean. *P<0.05, and **P<0.001 (Student’s t-test).
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tFigure 3. Normal CpG-driven upregulation of AICDA, CD23 and CD86 expression, activation of
NFκB, p38 MAP kinase and Rac1, and IL-6 secretion in B cells from DOCK8 deficient patients
(a) CpG-induced expression of mRNA for AICDA in PBMCs (left) and purified B cells
(right) from patients and controls (n= 2 each). (b,c) Percentage of CD19+ B cells expressing
surface CD23 and CD86 (left), and their MFI (right) before and after CpG stimulation of
PBMCs from patients and controls (n=3 each). (d) Representative (top) and quantitation
(expressed in lower panels as percent of control, n=3 each) of CpG-driven phosphorylation
of IκBα and p38 in PBMCs from patients and controls. IKKγ was used as loading control.
(e) CpG-driven IL-6 secretion by EBV-B cells from patients relative to controls (n=3 each,
mean for controls 55 pg/ml). (f) IFN-α secretion by pDCs in PBMCs from patients and
controls in response to stimulation with CpG-A ODN 2216 (n=3 each, mean for controls
22.4 pg/100 pDCs). The number of pDCs/culture was calculated from the percentage of
CD123+BDCA-4+ cells in each sample. (g) CpG-driven Rac1 activation in EBV-B cells
determined by a GST-PAK precipitation assay followed by immunoblotting for Rac1. Equal
volume aliquots of the lysates used in the pull-down assay were immunoblotted for Rac1 as
loading controls. Similar data was obtained on three different patients and controls in g;
(mean and s.e. in a–f).
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tFigure 4. CpG-induced DOCK8 dependent STAT3 phosphorylation in B cells is essential for B
cell proliferation and IgG production
(a,b) CpG-driven STAT3 Y705 phosphorylation in PBMCs (a) and purified B cells (b) from
DOCK8 deficient patients and controls. (c) IL-6 and IL-21 driven STAT3 Y705
phosphorylation in B cells from DOCK8 deficient patients. (d) Quantitation of CpG- and
IL-21-driven STAT3 Y705 phosphorylation in B cells from DOCK8 deficient patients and
controls (n=3 each). pSTAT3 and STAT3 bands were scanned by densitometry and the
pSTAT3/STAT3 ratio was calculated and expressed relative to the mean pSTAT3/STAT3
ratio in controls, which was arbitrarily set at 100% (n=3 per group). (e) CpG-driven STAT3
phosphorylation in total B cells and naïve B cells purified from the same donor. (f,g) CpG-
driven proliferation and Ig secretion (n=6 each) (f), and CD40/IL-4 driven proliferation and
IgE secretion (n=5 each) (g), by PBMCs from STAT3 deficient AD-HIES patients and
controls. (h) Effect of IL-6 (2 ng/ml) on CpG driven IgG secretion by PBMCs from DOCK8
deficient patients (n=3). Results are representative of three patients and three controls in a
and b, and three controls in e; mean and s.e. (d, h) and small horizontal lines indicate the
mean (f, g). NS, not significant; *P<0.01 and **P<0.001 (Student’s t-test).
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tFigure 5. CpG-driven phosphorylation of STAT3 in B cells is dependent on Syk, and requires
TLR9 and MyD88
(a,b) Syk phosphorylation following CpG stimulation (a) and anti-IgM stimulation (b) of
normal and DOCK8 deficient PBMCs detected by immunoblotting with anti-pY352Syk. (c)
Quantitation of CpG-driven and BCR-driven Syk Y352 phosphorylation in PBMCs from
DOCK8 deficient patients and controls. pSyk and BLNK bands were scanned by
densitometry and the pSyk/BLNK ratio was calculated and expressed relative to the mean
pSyk/BLNK ratio in controls, which was arbitrarily set at 100% (n=3 per group). (d) Effect
of the Syk inhibitor SYKINH-61 on CpG-driven STAT3 Y705 phosphorylation in normal
PBMCs. IL-21 driven STAT3 phosphorylation was used as a control. Results are
representative of three independent experiments. (e,f) Effect of SYKINH-61 on CpG-driven
and CD40 + IL21-driven proliferation (e), IgG production (f) by normal PBMCs (n=4). (g,h)
CpG-driven Syk Y352 and STAT3 Y705 phosphorylation in splenic B cells from Tlr9−/−
mice and C57BL/6 WT controls (g), and from Myd88−/− mice and BALB/c WT controls
(h). Mean and s.e. (c, e–f); NS, not significant; *P<0.05, **P<0.01, and ***P<0.001
(Student’s t-test).
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tFigure 6. DOCK8 mediates CpG activation of a Pyk2-Src-Syk-STAT3 cascade essential for B cell
proliferation and differentiation
(a,b) Representative immunoblot analysis of lysates from CpG-stimulated PBMCs from a
DOCK8 deficient patient and a normal control for tyrosine phophorylated proteins (a) and
for phosphorylation of Pyk2 at Y402 and Src at Y416 (b). BLNK was used as loading
control. The higher amounts of BLNK in PBMCs from the patients reflect the higher
percentage of CD19+ B cells in the patients compared to controls (23% versus 7 % in a and
19% versus 8% in b respectively). (c) Immunoblot analysis of lysates from CpG-stimulated
splenic B cells from Myd88−/− mice and BALB/c WT controls for pY402Pyk2 and
pY416Src. (d–g) Effect of the Pyk2 inhibitor tyrphostin A9 (Tyr A9) and the Src kinase
inhibitor PP2 on CpG-driven phosphorylation of Pyk2 at Y402 (d), Src at Y416 (e), Syk
Y352 (f), and STAT3 at Y705 (g) in normal PBMCs. (h) Effect of Tyr A9 and PP2 on CpG-
driven IgG secretion by normal PBMCs. Stimulation with anti-CD40+IL-21 was used as
control. Results in (a–g) are representative of three independent experiments. Data in (h)
represent mean and s.e. of three experiments. *P<0.05 and **P<0.01 (Student’s t-test).
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tFigure 7. DOCK8 associates with MyD88 and Pyk2 and undergoes Pyk2-mediated tyrosine
phosphorylation and association with Src/Lyn following TLR9 ligation
(a,b) Association of DOCK8 with MyD88 in 293T cell transfectants (a) and in EBV-B cells
(b). (c,d) Association of Pyk2 and MyD88 in EBV-B cells from control (C) and DOCK8
deficient (def) patient (c) and of Pyk2 and DOCK8 EBV-B cells from control (C) and
MyD88 def patient (d). Results in a–d are representative of three experiments. (e) DOCK8
tyrosine phosphorylation and association with Src following CpG stimulation of normal B
cells. DOCK8 immunoprecipates were probed with anti-p-Tyr, anti-Src and anti-DOCK8 as
loading control. Equal volumes of lysates were probed for Src and DOCK8. (f) CpG- driven
Lyn phosphorylation in normal PBMCs. Lyn immunopreciptates were probed with anti-
pY416Src and with anti-Lyn as loading control. (g) Lyn recruitment to DOCK8 following
CpG stimulation of normal PBMCs with CpG. DOCK8 immunoprecipitates were probed
with anti-Lyn and anti-DOCK8 as loading control. Upper panel: representative experiment.
Lower panel: quantitative analysis of the lyn/DOCK8 band intensity ratio (n=3, mean and
s.e.).
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Table 1
IgG antibody titers in immunized DOCK8 deficient patients
% with protective antibody titer
TT HepB HiB PV
DOCK8-deficient patients (n = 5) 40% 0% 20% 20%
Normal children (n= see legend) >99% >99% 83–97% 50–100%
Frequency of protective IgG antibody titers to TT, HepB, HiB, and PV in five immunized DOCK8-deficient patients who received a full course of
immunization with the vaccines, compared to published values in normal controls cited in Ref. 25 and the vaccine prescribing information. The
numbers of normal children were 3,032 for TT, 147 for HepB, 3,486 for HiB and 18,906 for PV. Antibody titers were obtained prior to
replacement with gammaglobulin. Values for protective antibody titers were provided by the clinical laboratory where the test was performed.
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